Key Metrics 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Ciba India Ltd (CIBASPEC)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532184 NSE: CIBASPEC Chemicals | Small Cap | Ciba India Share Price
BSE Share Price
Not Listed
Not Listed
Ciba India Ltd (CIBASPEC)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532184 NSE: CIBASPEC Chemicals | Small Cap | Ciba India Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹438 Cr.
Current Price
₹0
52-Week Low / High
₹321 / 333
TTM EPS
₹24.7
TTM Sales
₹692 Cr.
Book Value per Share
₹298.1
P/E Ratio
13.37
Industry PE
49.5
Price to Book (P/B)
1.11
Price to Sales (P/S)
0.63
EV/EBITDA
6.56
Dividend Yield
INF%
Profitability Efficiency
Return on Equity (ROE)
8.70%
Return on Capital Employed (ROCE)
12.76%
Return on Assets (ROA)
6.29%
Operating Profit Margin
9.1%
Net Profit Margin
4.81%
Gross Profit Margin
9.3%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
8.13%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
-4.4%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
7.88%
Asset Quality
Promoter Holding
71.40%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹383 Cr.
Equity
₹13.3 Cr.
Face Value
₹10
All Time Low / High
₹47.00 / 669.90
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation ⓘ
| Mar'00 | Mar'01 | Mar'02 | Mar'03 | Mar'04 | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 25.8% | 28.5% | 26.3% | 15.1% | 11% | 19% | 25% | 37.9% | 10.9% | 11.2% | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 440 | 480 | 478 | 488 | 454 | 561 | 624 | 511 | 468 | 506 | 445 |
| Sales YoY Gr. | - | 9.2% | -0.6% | 2.2% | -6.9% | 23.4% | 11.3% | -18.1% | -8.4% | 8.1% | - |
| Adj EPS ⓘ | 13.8 | 10.1 | 17.5 | 14.1 | 10.2 | 20.2 | 25 | 29.3 | 15.4 | 18.8 | -22 |
| YoY Gr. | - | -26.7% | 72.5% | -19.5% | -27.8% | 99.1% | 23.5% | 17.3% | -47.5% | 21.9% | - |
| BVPS (₹) ⓘ | 75.9 | 90.4 | 109.8 | 119.1 | 125.7 | 139.9 | 157 | 211.8 | 222.3 | 235 | 220.2 |
| Adj Net Profit ⓘ | 18.4 | 13.5 | 23.2 | 18.7 | 13.5 | 26.9 | 33.2 | 38.9 | 20.4 | 24.9 | -29 |
| Cash Flow from Ops. ⓘ | 24.1 | 5.2 | 23.4 | -2.9 | 48.7 | 39.1 | 35.6 | -8.9 | 23.6 | 7.6 | - |
| Debt/CF from Ops. ⓘ | 1 | 11.7 | 2.4 | -27.9 | 1.7 | 0.6 | 0.1 | -0.9 | 1 | 0.2 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 1.6% | 2.2% | -6.7% | 8.1% | ||||
| Adj EPS ⓘ | 3.5% | 13.1% | -9.1% | 21.9% | ||||
| BVPSⓘ | 13.4% | 13.3% | 14.4% | 5.7% | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Mar'00 | Mar'01 | Mar'02 | Mar'03 | Mar'04 | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 19.3 | 12.2 | 17.5 | 12.3 | 8.3 | 15.2 | 16.8 | 15.9 | 7.1 | 8.2 | -9.7 |
| Op. Profit Mgn % ⓘ | 7.6 | 5.6 | 6.7 | 6.8 | 5.4 | 8 | 8.2 | 6.4 | 6.9 | 7.4 | -1.3 |
| Net Profit Mgn % ⓘ | 4.2 | 2.8 | 4.9 | 3.8 | 3 | 4.8 | 5.3 | 7.6 | 4.4 | 4.9 | -6.6 |
| Debt to Equity ⓘ | 0.2 | 0.5 | 0.4 | 0.5 | 0.5 | 0.1 | 0 | 0 | 0.1 | 0 | - |
| Working Cap Days ⓘ | 101 | 113 | 129 | 144 | 162 | 128 | 133 | 155 | 160 | 163 | 0 |
| Cash Conv. Cycle ⓘ | 42 | 60 | 74 | 87 | 97 | 72 | 62 | 65 | 59 | 56 | 0 |
Valuation of Ciba India - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'02 | Mar'03 | Mar'04 | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 |
|---|---|---|---|---|---|---|---|---|
| Sales | 541.65 | 558.84 | 534.42 | 646.86 | 747.66 | 659.04 | 637.72 | 691.96 |
| Operating Expenses ⓘ + | 494.14 | 508.42 | 488.22 | 583.22 | 667.19 | 592.16 | 577 | 633.91 |
| Operating Profit ⓘ | 47.51 | 50.42 | 46.20 | 63.64 | 80.47 | 66.88 | 60.72 | 58.05 |
| Operating Profit Margin (%) | 8.8% | 9.0% | 8.6% | 9.8% | 10.8% | 10.1% | 9.5% | 8.4% |
| Other Income ⓘ + | 28.65 | 13.76 | 10.35 | 5.73 | 7.49 | 11.35 | 11.79 | 10.68 |
| Interest ⓘ | 7.86 | 6.28 | 6.14 | 4.08 | 2.33 | 1.56 | 2.46 | 3.21 |
| Depreciation ⓘ | 17.88 | 17.22 | 18.88 | 18.89 | 18.03 | 16.23 | 18.90 | 18.78 |
| Profit Before Tax ⓘ | 50.41 | 40.68 | 31.54 | 46.39 | 67.61 | 154.72 | 51.15 | 48.26 |
| Tax ⓘ | 8.90 | 12.56 | 11.44 | 17.66 | 27.71 | 22.60 | 20.31 | 14.99 |
| Profit After Tax | 41.51 | 28.12 | 20.10 | 28.73 | 39.89 | 132.12 | 30.84 | 33.27 |
| PAT Margin (%) | 7.7% | 5.0% | 3.8% | 4.4% | 5.3% | 20.1% | 4.8% | 4.8% |
| Adjusted EPS (₹) | 27.6 | 16.6 | 13.2 | 21.6 | 30.0 | 98.8 | 23.1 | 24.7 |
| Dividend Payout Ratio (%) | 32.60% | 27.20% | 30.30% | 25.40% | 23.30% | 5.10% | 15.10% | 14.20% |
| PARTICULARS | Mar'02 | Mar'03 | Mar'04 | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 146.20 | 161.46 | 172.36 | 192.33 | 221.62 | 344.31 | 368.64 | 395.96 | |||
| Debt + | 61.21 | 77.13 | 75.16 | 14.34 | 15.91 | 13.47 | 27.47 | 14.38 | |||
| Minority Interest | 17.32 | 20.22 | 0 | 0 | 0 | 8.99 | 9.1 | 0 | |||
| Trade Payables | 48.73 | 67.89 | 54.82 | 80.91 | 120.97 | 70 | 91.46 | 75.11 | |||
| Others Liabilities ⓘ | 33.37 | 32.89 | 33.98 | 37.97 | 42.62 | 37.09 | 35.49 | 40.38 | |||
| Total Liabilities ⓘ | 306.84 | 359.60 | 336.32 | 325.54 | 401.12 | 473.85 | 532.16 | 525.82 | |||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 68.92 | 64.64 | 71.42 | 66.14 | 59.14 | 117.05 | 123.70 | 132.86 | |||
| CWIP ⓘ | 1.96 | 0.73 | 1.18 | 1.94 | 32.17 | 16.51 | 16.85 | 4.07 | |||
| Investments ⓘ | 38.57 | 38.93 | 39.20 | 0.87 | 2.71 | 103.01 | 119.64 | 111.43 | |||
| Inventories | 77.36 | 99.69 | 88.68 | 90.74 | 119.36 | 95.36 | 117.09 | 110.74 | |||
| Trade Receivables | 97.41 | 130.70 | 111.73 | 138.42 | 151.73 | 101.36 | 104.52 | 99.62 | |||
| Cash Equivalents | 0.72 | 2.08 | 4.03 | 6.03 | 3.55 | 1.74 | 2.47 | 1.71 | |||
| Others Assets ⓘ | 21.90 | 22.82 | 20.08 | 21.40 | 32.45 | 38.82 | 47.89 | 65.40 | |||
| Total Assets ⓘ | 306.84 | 359.60 | 336.32 | 325.54 | 401.12 | 473.85 | 532.16 | 525.82 | |||
| PARTICULARS | Mar'02 | Mar'03 | Mar'04 | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 |
|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 37.23 | 10.48 | 63.83 | 47.59 | 47.95 | 10.28 | 34.92 | 16.78 |
| Cash Flow From Investing Activity ⓘ + | -9.16 | -5.84 | -42.16 | 25.88 | -40.93 | 5.73 | -38.98 | 9.76 |
| Cash Flow From Financing Activity ⓘ + | -28.48 | -3.29 | -19.71 | -71.47 | -9.49 | -17.83 | 4.79 | -27.30 |
| Net Cash Flow ⓘ | -0.42 | 1.35 | 1.96 | 2 | -2.47 | -1.81 | 0.73 | -0.76 |
| PARTICULARS | Mar'02 | Mar'03 | Mar'04 | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 28.39 | 18.28 | 12.04 | 15.76 | 19.27 | 46.69 | 8.65 | 8.7 | ||
| ROCE (%) | 28.1 | 21.06 | 15.5 | 22.23 | 31.49 | 52.5 | 14.22 | 12.76 | ||
| Asset Turnover Ratio | 1.82 | 1.73 | 1.59 | 2.02 | 2.13 | 1.56 | 1.31 | 1.33 | ||
| PAT to CFO Conversion(x) | 0.9 | 0.37 | 3.18 | 1.66 | 1.2 | 0.08 | 1.13 | 0.5 | ||
| Working Capital Days | ||||||||||
| Receivable Days | 63.70 | 72.20 | 80.20 | 68.20 | 68.50 | 67.70 | 57.20 | 53 | ||
| Inventory Days | 50.60 | 56.10 | 62.30 | 48.90 | 49.60 | 57.40 | 59.10 | 59.10 | ||
| Payable Days | 41.40 | 48 | 52.50 | 48.20 | 63.60 | 68.70 | 60.40 | 57 | ||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Ciba India Ltd FAQs
The current trading price of Ciba India on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Ciba India stood at ₹438.3 Cr
The latest P/E ratio of Ciba India as of 31-Dec-1969 is 0.00.
The latest P/B ratio of Ciba India as of 31-Dec-1969 is 1.50.
The 52-week high of Ciba India is ₹332.9 and the 52-week low is ₹321.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Ciba India is ₹445 ( Cr.) .
Data is not available for this company.
No data found
No data found
About Ciba India Ltd
Ciba India, formerly known as Ciba Specialty Chemicals (India), is engaged in the manufacturing, selling and trading of a wide range of specialty chemicals. It was formed when the chemicals division of Hindustan Ciba-Geigy was hived off in 1996 and got its present name on December 19, 2007. The company is a part of Ciba, headquartered in Basel, Switzerland, with business interests in plastics, paper, automobiles, buildings, home and personal care products across more than 120 countries. The group's plant is located at Goa. The company offers specialty chemicals such as additives, coating chemicals, water treatment and paper treatment chemicals, home and fabric care chemicals and personal care chemicals to a number of industries including petrochemicals, lubricants, oil & gas, automobiles, paper, paints, plastics, inks, electronics material, packaging, water treatment, and home & personal care products.
The manufacturing facility located at Santa Monica in Goa is a global sourcing point for Ciba. Since March 2007, this facility manufactures UV absorbers. It continues to manufacture textile chemicals for Huntsman International (India) as a part of the agreement relating to sale of the erstwhile textile affects business. A research and technology center in Mumbai conducts specialized research and development activities. The business segments align closely with customer industries by offering integrated and complete solutions including a wide range of knowledge-based services and expertise and follow a tailored approach to individual customer needs creating strategic partnerships that link core competencies of the company with end-user markets. Virchow Drugs, a subsidiary, manufactures the antibacterial agent triclosan, which is used in personal care products like toothpaste, soaps and fabrics.
The registered office is located at Plot No. 37, Chandivali Farm Road, Chandivali, Andheri (East), Mumbai-400072.
Divisions:
- Speciality chemicals segment - This segment includes coating chemicals, additives, water treatment and paper treatment chemicals, home and fabric care chemicals and personal care chemicals.
- Other - The other segments include manufacture of under-contract and sourcing of products for exports.
You have 48 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
